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Background 
 
Cellular metabolism. 
Cellular metabolism is the summary of all the biochemical reactions taking 
place within a cell. Metabolism is organized in sequences of biochemical 
reactions called pathways. They can be linear sequences of a few reactions, or 
extensively branched with reactions converging on or diverging from a central 
main pathway.  
Metabolism is divided into two broad categories: 
1) catabolism, which is the combination of the pathways that break down large 
molecules such as polysaccharides, lipids, nucleic acids and proteins into 
smaller units including monosaccharides, fatty acids, nucleotides, and amino 
acids, respectively. All these reactions provide energy which is used to drive 
the synthesis of adenosine triphosphate (ATP). The monomers, released from 
breaking down polymers, are used to construct new polymer molecules and to 
maintain cell growth. Examples of catabolic processes include glycolysis, 
the citric acid cycle (TCA), the breakdown of proteins in order to use amino 
acids as substrates for gluconeogenesis and the breakdown of fat in adipose 
tissue to fatty acids (Figure 1). 
2) anabolism is the set of pathways that construct molecules from smaller units 
provided by catabolism. Many anabolic processes are powered by the 
hydrolysis of ATP. The main function of the anabolic pathways is to synthesize 
the four classes of macromolecules essential for the 
cell: polysaccharides, lipids, nucleic acids and proteins.  The most important 
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anabolic pathways are gluconeogenesis, pentose phosphate shunt (PPP), 
protein and lipid synthesis (Figure 1).  
Metabolism is a dynamic process. The cell is continuously degrading and 
synthesizing molecules and this constant turnover of cellular materials keeps 
the cell in good condition. Cellular metabolism is the most fundamental level 
where the dynamic properties of life begin to appear. The complex interactions 
of different  pathways, their regulation, and their organization demonstrate the 
perfect refinement of the biochemistry of life. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Overview of cellular metabolism 
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The Warburg effect 
Our common knowledge of metabolic pathways is principally based on studies 
performed on non proliferating cells in differentiated tissues. In normal cells, 
the metabolism of the basic energy substrates (carbohydrates, proteins, and 
lipids), generates several metabolic intermediates that are used to synthesize 
nucleic acids, nonessential amino acids, glycogen, and other biomolecules 
required for normal body functioning. Since energy is critical to all biologic 
processes, metabolism partly results in the production of acetyl CoA that is 
oxidized in the TCA cycle to produce reducing equivalents necessary for 
energy generation by the respiratory chain. Carbohydrates are broken down to 
glucose, which is taken up by cells and metabolized via the fundamental 
biochemical process known as glycolysis. Glucose enters in the cell through 
specific glucose transporters (GLUTs) (1), which include a large family of 
plasma membrane proteins (GLUT-1, GLUT-2). 
In the cytosol, several enzymes catalyze glycolysis that ends with the 
production of pyruvate and two molecules of ATP per glucose. Pyruvate enters 
the mitochondria and is converted to acetyl CoA by pyruvate dehydrogenase 
(PDH). Acetyl CoA condenses with oxaloacetate (OAA) to form citrate, which is 
completely oxidized in the TCA cycle to generate reducing equivalents for the 
respiratory chain. The respiratory chain produces ~34 ATP molecules per 
glucose, bringing the total number of ATPs produced per complete oxidation of 
glucose to ~36, which accounts for over 90% of the energy requirements of the 
normal cell (2). Thus, in normal cellular intermediary metabolism, glycolysis, 
TCA cycle and respiratory chain activities are tightly linked and regulate. 
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The most noticeable features of proliferating cancer cells are their ability to 
uptake huge amounts of glucose and to sustain high rates of glycolysis for 
ATP generation, independently from oxygen availability. This phenomenon is 
known as “Warburg effect”, from the name of its discoverer Otto Warburg 
(Figure 2) (3-5). To explain this event, he firstly hypothesized a defect in 
mitochondrial respiration as a cause for the increased aerobic glycolysis in 
tumor cells. However, it was later appreciated that mitochondrial defects are 
uncommon in malignant cells (6) and that most tumours maintain the capacity 
for oxidative phosphorylation and they consume oxygen at rates similar to 
those observed in normal tissues (7). Other explanations consider that 
glycolysis has the capacity to generate ATP at a higher rate than oxidative 
phosphorylation and so would be beneficial as long as glucose supplies are 
not limited. In turn, it has been proposed that glycolytic metabolism derives 
from an adaptation to hypoxic tumor microenvironment, as it allows for ATP 
production in the absence of oxygen (8, 9). In addition, enhanced uptake of 
glucose and its conversion into lactate creates the problem of intracellular 
acidification and lactate accumulation (10,11). The lactate produced is 
secreted out of the cells to warrant cancer cell survival and to keep aerobic 
glycolysis active. Moreover, different studies suggest that extracellular lactate 
facilitates immune escape, migration, metastasis, tumor vascularization and 
radioresistance (12-14). The most recent explanation for the switch to aerobic 
glycolysis by tumor cells, is that proliferating cells have important metabolic 
requirements that extend beyond ATP. Tumor cells must replicate all of its 
cellular contents to sustain mitosis. This aspect imposes a large requirement 
for nucleotides, amino acids, and lipids. During growth, glucose is used to 
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generate biomass as well as produce ATP whose hydrolysis provides free 
energy to sustain anabolic pathways (11). 
New evidences suggest that the Warburg effect is a strategy, used by cancer 
cells, not only to face up to multiple urgent requirements simultaneously for 
growth and proliferation but also to reduce reactive oxygen species (ROS) and 
therefore oxidative stress. 
The Warburg effect has found widespread clinical utility in the imaging of 
cancer using 18(F)-Fluorodeoxyglucose (2-fluoro-2-deoxy- D-glucose – FDG) 
in positron emission tomography (PET) scans. A glucose analog, 2-fluoro-2-
deoxy-D-glucose, is, therefore, taken up at higher concentrations in cells with 
increased glucose transport such as malignant cells. Intracellular FDG is 
phosphorylated by hexokinases (HK) to FDG-6-phosphate, which cannot be 
metabolized further in glycolysis. Thus, FDG-6-phosphate accumulates in the 
cell and the radioactive isotope fluorine-18 enables imaging of the cell before 
radioactive decay. The technology is used in the diagnosis, staging, and 
monitoring of several cancers, including lymphoma, melanoma, and cancers of 
the colon, breast, and lung (15). 
 
 
Figure 2. The Warburg effect 
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The PI3K/ATK/mTOR pathway. 
Mutations that activate oncogenes or inactivate tumor suppressors can 
significantly affect activities of metabolic enzymes and have a key role in 
aerobic glycolysis of cancer. Among oncogenic mutations, hyperactivation of 
the phosphatidylinositol 3′-kinase (PI3K)/Protein kinase B (AKT)/mammalian 
target of rapamycin (mTOR) axis initiates a signal transduction cascade that 
promotes cancer cell growth, survival and metabolism (16, 17). 
PI3Ks are a family of lipid kinases that propagate intracellular signaling 
regulating a wide range of cellular processes.  There are three distinct classes 
of PI3K, but the IA PI3Ks is the most implicated in cancer cell growth and 
survival. Class IA PI3Ks are activated by growth factor receptor tyrosine 
kinases (RTKs). As shown in figure 3, both insulin and insulin growth factor 1 
(IGF1) receptors use the insulin receptor substrate (IRS) family of adaptor 
molecules to engage class IA PI3Ks, whereas other receptors, such as the 
platelet-derived growth factor (PDGF) receptor, recruit class IA PI3Ks directly 
(18). IA PI3Ks phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) on 
the plasma membrane to generate the second messenger, 
phosphatidylinositol-3,4,5-trisphosphate (PIP3). The accumulation of PIP3 on 
the cell membrane leads to the recruitment and the activation of protein with 
pleckstrin homology (PH) domain known as phosphoinositide-dependent 
protein kinase 1 (PDK1) which phosphorylates Akt at T308. The full activation 
of Akt is provided by S473 phosphorylation mTORC2-mediated (Figure 3) (19, 
20). Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) by 
dephosphorylating the 3′ position of phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) to phosphatidylinositol 4,5-bisphosphate (PIP2), antagonizes the PI3K-
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Akt signaling pathway (21). The central biological consequences of Akt 
activation can be classified into three categories, survival, proliferation, and 
growth. Moreover, Akt has important effects on tumor-induced angiogenesis 
that is partly mediated by hypoxia-inducible factor-1  (HIF-1 ) and vascular 
endothelial growth factor (VEGF) (22). Akt has an anti-apoptotic function 
through BAD-phopshorylation, a member of BCL2 family of proteins that 
promotes cells death (23). Although Akt inhibits apoptosis through pro-death 
protease Caspase-9 and forkhead box O transcription factors (FoxO) 
phosphorylation (24, 25), it can also influence the activity of the pro-apoptotic 
tumor suppressor p53, through phosphorylation of the p53-binding 
protein MDM2 (26, 27).  
Several studies demonstrated that p53 plays an important role as regulator of 
metabolism. For example, p53 activates the expression of hexokinase 2 (HK2), 
which converts glucose to glucose-6-phosphate (G6P). G6P is directed 
through glycolysis and PPP to produce ATP and to support macromolecules 
biosynthesis. p53 inhibits the glycolytic pathway by upregulating the 
expression of TP53-induced glycolysis and apoptosis regulator (TIGAR), an 
enzyme that decreases the levels of the glycolytic activator fructose-2,6-
bisphosphate (28-30).  
The cell cycle is regulated by the orchestrated action of cyclin–cyclin-
dependent kinase (CDK) complexes and CDK inhibitors (CKIs). Cyclin D1, 
which is implicated in the G1/S phase transition, is phoshorylated by the cyclin 
D1 kinase glycogen synthase kinase-3 (GSK3β) and degradated by the 
proteasome. Akt directly inhibits GSK3β allowing to Cyclin D1 accumulation 
and supporting tumor cell proliferation (Figure 3) (31). In addition to its role in 
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proliferation, there is growing evidence that Akt also affects the synthesis of 
macromolecules, which results in increased cell mass or size, a process that is 
enhanced in cancer cells to meet the biosynthetic requirements that are 
imposed by the augmented degree of proliferation.  
The “main character” involved in the PI3K-pathway is mTOR, a 
serine/threonine kinase that acts as a molecular sensor regulating protein 
synthesis on the basis of nutrients availability. mTOR exists in two distinct 
intracellular complexes, mTOR complex 1 and 2 (mTORC1 and mTORC2). 
mTORC1 is a complex of mTOR with regulatory-associated protein of mTOR 
(raptor), LST8 and Akt1 substrate 1 (AKTS1). Unlike mTORC2, mTORC1 is 
effectively inhibited by rapamycin and its analogues (32). mTORC1 
phosphorylates p70 S6 kinase and 4E-binding protein 1 (4EBP1), 4EBP2 and 
4EBP3. These phosphorylation events imply the increased translation of 
mRNAs that encode many cell cycle regulators (33). mTORC1 activity is 
controlled by the tuberous sclerosis 1 (TSC1)–TSC2 complex which functions 
as a GTPase-activating protein (GAP) for the small G protein Ras homologue. 
TSC2 is directly phosphorylated in response to growth factor signalling such as 
PI3K–Akt and ERK–Rsk signaling and energy homeostasis through AMP-
activated protein kinase (AMPK) (34). Akt1 stimulates aerobic glycolysis by 
promoting the synthesis and incorporation of GLUT1 into the plasma 
membrane (35-37); by stabilizing the association between HK2 and 
mitochondria, hence increasing its enzymatic activity (38) and by activating 6-
phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) (39). In 
addition, Akt1 stimulates lipid biosynthesis by increasing the activity of ATP 
citrate lyase (ACLY).  
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Figure 3. Molecular mechanism of the PI3K/Akt/mTOR pathway 
 
 
ROS: a double edge sword 
The term reactive oxygen species concerns several molecules derived from 
oxygen that have accepted extra electrons and can oxidize other molecules 
(40). Specificity in ROS signalling takes advantage of the distinct biological 
properties of each oxidant species, which include their chemical reactivity, 
stability, and lipid diffusion capabilities. As shown in Figure 4, O2− is generated 
by the cytosolic NADPH oxidases (NOXs) (41, 42) through the one-electron 
reduction of O2 occurring in mitochondrial electron transport chain (ETC) 
complexes I, II, and III (43, 44).  
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Figure 4. The generation and consequences of ROS in mitochondria. 
 
Cytosolic O2− is rapidly converted to H2O2 by the enzymatic activity of 
superoxide dismutase 1 (SOD1). O2− generated by the mitochondrial ETC is 
released into the matrix where it is quickly dismutated to H2O2 by superoxide 
dismutase 2 (SOD2). Complex III-generated O2− is also released into the 
intermembrane space where it can traverse through voltage-dependent anion 
channels into the cytosol and be converted into H2O2 by SOD1. In addition, 
H2O2 is produced in the endoplasmic reticulum (ER) as an end product in 
numerous peroxisomal oxidation pathways such as in the β-oxidation of very 
long-chain fatty acids, and by a wide range of enzymes including cytochrome 
P450 (45). A well known mechanism of redox signalling involves H2O2-
mediated oxidation of cysteine residues within proteins. Cysteine residues 
exist as a thiolate anion (Cys–S-) at physiological pH and are more susceptible 
to oxidation compared with the protonated cysteine thiol (Cys–SH). During 
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redox signalling, H2O2 oxidizes the thiolate anion to the sulfenic form (Cys–
SOH), causing allosteric changes within the protein. This event alters protein 
function. The sulfenic form can be reduced to thiolate anions by the disulfide 
reductases thioredoxin (Trx) and glutaredoxin (Grx) to return the protein 
function to its original state. Hence, the oxidation of cysteine residues within 
proteins could represent a mechanism to reverse signal transduction 
mechanism. Nonetheless, higher level of H2O2 causes oxidative stress, 
damaging proteins. Therefore, cells have professional enzymes dedicated to 
prevent the build-up of intracellular H2O2 such as peroxiredoxins and 
glutathione peroxidises.  
Cancer cells constitutively activate growth factor pathways to sustain cellular 
growth and proliferation (Figure 5). Consequently, tumor cells show an “hyper-
metabolism” linked to an abnormal generation of ROS from mitochondria and 
the endoplasmic reticulum, which cause genomic instability (46). Moreover, the 
high levels of ROS activate signalling pathways proximal to the mitochondria to 
promote cancer cell proliferation and tumorigenesis (46). In fact, ROS can i) 
inhibit phosphatases such as PTEN, to dysregulate PI3K signalling resulting in 
increased Akt signalling and enhanced proliferation and survival (47) ii) over 
express HIFs, regulating metabolic adaptation to hypoxia and the expression 
of pro-angiogenic genes such as vascular endothelial growth factor (VEGF) 
(48) iii) activate MAPK pathway and NF-B to enrich the antioxidant 
counterparts to avoid ROS cell death-mediated (Figure 5) (49). 
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Figure 5. Signaling pathway acticvated by ROS. 
 
Indeed, ROS are also a major contributor to oxidative damage (50). Thus the 
cellular levels of ROS must be balanced  in order to promote cancer cell 
growth and proliferation without causing severe oxidative damage and cell 
death. ROS production in cancer cells is elevated due to oncogenic stimulation 
and increased metabolic activities (51). The Warburg effect, which leads to the 
production of NADPH and thus a proper redox status, becomes an important 
survival mechanism for cancer cells. In fact, one of the most important feature 
of the Warburg effect is the switch of the isoform of pyruvate kinase (PK), 
which catalyzes the conversion of phosphoenolpyruvate (PEP) to pyruvate as 
the last step of glycolysis. Many tumor cells use the M2 isoform of pyruvate 
kinase (PKM2) instead of the M1 isoform of the enzyme (PKM1) as normal 
tissues do (Figure 6) (52-54). PKM2 has an enzymatic activity lower than 
PKM1. This event leads to the upregulation of glucose uptake and 
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accumulation of  earlier glycolytic intermediates, such as PEP. This, in turn, 
triggers PPP producing more NADPH which reduces ROS. In addition, ROS 
and PKM2 form a negative feedback loop to maintain ROS in a tolerable and 
functional range. Since ROS contribute to mitogenic signalling, reducing 
intracellular ROS levels could represent a new strategy to inhibit cancer 
growth. Contrary to the expected results, in several large-scale studies, it has 
been demonstrated that supplementation of antioxidant molecules increased 
the risk of cancer (55, 56). A more promising strategy seems to be blocking 
antioxidant pathways or stimulating ROS production. Both methods lead to the 
accumulation of toxic levels of intracellular ROS pushing cells to die (57) 
(Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Linking ROS to the Warburg effect. 
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Targeting the Warburg effect to treat cancer.  
Some of the most important features of the Warburg effect are: (i) increased 
expression of GLUTs and increased glucose uptake; (ii) increased PPP-
catalyzed NADPH production; (iii) altered activities of  glycolytic enzymes and 
(iv) increased lactate production. Some of these features could potentially be 
targeted to develop new strategies for cancer therapy.  
Up to 90% of all cancers are characterized by upregulation of GLUT 
expression and glucose metabolism. At least, 12 GLUTs have been identified, 
but the major role in cancer have been associated to GLUT1 and GLUT2 (58). 
Several in vivo studies demonstrated that GLUT1 inhibition represents a 
compelling anticancer strategy (59-61). Furthermore, drugs targeting glycolytic 
enzymes, in particular HK and LDH inhibitors, could represent good strategy to 
suppress tumorigenesis. These agents could inhibit tumor growth by 
decreasing metabolic precursors for glycolysis, slowing down synthesis of 
biomass and reducing equivalents and causing ROS dysregulation. 
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Calorie restriction 
Definition  
In the last century life expectancy at birth has markedly increased from about 
45 years at the beginning of the 20th Century to about 77 years today in many 
developed countries, including Western Europe, USA, Canada, Japan, 
Australia, and New Zealand (62). However, the increase in life expectancy 
does not go hand in hand with the quality as evidenced by the rising burden of 
chronic diseases, including abdominal obesity, type 2 diabetes, chronic lower 
respiratory disease, Alzheimer’s disease, heart and cerebrovascular diseases, 
and cancer (63). Almost 80% of older adults (+65 years) have at least one of 
the above mentioned chronic diseases, and 50% have at least two chronic 
diseases (Figure 7). The main risk factors for the above mentioned chronic 
diseases are associated to i) the consumption of foods high in caloric intake 
but devoid of nutrients (e.g., vitamins, phytochemicals), ii) physical inactivity 
and iii) smoking (64). 
Aging is a biological and psychological process, not due to illness , occurring in 
all individuals after maturity which gradually reduce the ability of the organism 
to adapt to stress and to maintain the homeostasis. Aging depends on genetic 
factors for 30% and on the environment for 70%. It is irreversible and produces 
an increased susceptibility to the disease. Oxidative damage to cell 
components, caused by an imbalance between ROS and antioxidant systems, 
is considered the most important player in causing this phenomenon. Indeed, 
aging is accompanied by progressive accumulation of oxidative damage in 
many tissues, including the peripheral and central nervous systems (PNS, 
CNS) (65-68). 
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Biogerontology studies performed in the past decade indicate that dietary 
modification or genetic manipulations extend longevity by producing a shift to a 
maintenance mode characterized by enhanced stress resistance. The 
longevity and stress-resistance regulation can be obtained by mutations that 
decrease the activity of nutrient-signaling pathways or by reducing calorie 
intake by at least 30%, without malnutrition, a strategy called dietary or calorie 
restriction (DR/CR) (69, 70). Calorie restriction triggers highly conserved 
survival mechanisms that enhance the protection of organisms ranging from 
bacteria, yeast, worms, flies, and mice, to non-human primates against various 
types of stress and/or disease including diabetes, cardiovascular disease and 
cancer. This counterintuitive effect is mediated in part by the reduction of 
conserved nutrient-signaling pathways that include several mitogenic 
components, especially the IGF-I receptor and its downstream effectors (69, 
71-74). 
 
 
Figure 7. Causes of death in adults aged 65 years or older  
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Calorie restrictrion in model organism. 
CR remains the most robust non-genetic nutritional experimental intervention 
for life extension in many species, including yeast, fruit flies, nematodes, fish, 
rats, mice, and monkeys (75). Invertebrate model organisms, such as yeast, 
Caenorhabditis elegans (C. elegans) and Drosophila, are largely exploited to 
understand the molecular anti-aging mechanisms of CR.   
Mutations involved in the extension of lifespan were first discovered in C. 
elegans, and led to the discovery of the role of the insulin/Igf-like (IIS) axis in 
aging (76). 
The impairment of IIS pathway by CR, in yeast Saccharomyces cerevisiae, C. 
elegans and in Drosophila causes the down regulation of PI3K/mTOR/Akt 
pathway activity (Figure 8). As consequence, it is possible to observe the 
activation or inhibition of different transcription factors, (such as Forkhead 
FoxO transcription factor, eIF4E-binding proteins (4E-BP) involved in i) cellular 
stress-response ii) detoxification of xenobiotics and free radicals and iii) protein 
translation (77, 78). However, the metabolic, anatomical, physiological and 
lifespan differences between these invertebrate model organisms and the 
mammalian systems are enormous.  
Rodents provide an extremely valuable and flexible animal model in which to 
determine the ability of CR to extend maximum lifespan and healthspan in a 
mammalian system. 
Mutation in the growth hormone receptor (GHR) and mutations that cause 
GH/IGF-I deficiency represent the genetic interventions causing the longest life 
span extension in mammals (79). 
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In agreement with the results in worms and flies discussed earlier, inhibition of 
the mTOR pathway beginning at 600 days of age extends median and 
maximal lifespan of mice (80) and the deletion of ribosomal S6 protein kinase 
1 (S6K1), a component of the mTOR signaling pathway, leads to increased life 
span and resistance to age-related pathologies, including bone, immune, and 
motor dysfunction and insulin resistance (81). The connection between signal 
transduction pathways and stress resistance in mammals may involve 
transcription factors including the orthologs of the anti-aging transcription 
factors described in yeast, worms and flies (Figure 8).  
CR, without malnutrition, in mice and rats has been clearly demonstrated to 
increase both average and maximal lifespan by preventing or delaying the 
occurrence of a wide range of chronic diseases and by inhibiting spontaneous, 
chemically- and radiation-induced cancer (82). CR has also been shown to 
prevent or delay the occurrence of chronic nephropathies and 
cardiomyopathies, diabetes, autoimmune and respiratory disease (75) and 
decreases neurodegeneration in the brain of animal models of Alzheimer 
disease, Parkinson disease, Huntington disease, and stroke (83, 84). Similar 
to rodents, in monkeys CR determines a significant reduction of age-related 
diseases such as cancer and cardiovascular disease. Moreover, CR protects 
monkeys against obesity and diabetes and stimulates immune system function 
(85). 
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Figure 8. A model for the conserved nutrient signalling pathways that regulate longevity 
in various organisms and mammals 
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Calorie restriction in humans. 
In humans, CR refers only to a state in which energy intake is sufficiently low 
to achieve or maintain a low-normal body weight status (i.e., body mass 
index<21 kg/m2) without causing malnutrition (i.e., adequate intake of proteins 
and micronutrients) (64). Epidemiological studies, conducted on the 
inhabitants of Okinawa (Japan), which mainly consume vegetables and fish 
with a daily calorie intake 40% less in comparison to that of a Japanese or US 
resident (86), showed that Okinawans have a delay or sometime an escape of 
chronic diseases of aging including dementia, cardiovascular disease and 
cancer. 
Since 1991 to 1993, in Arizona, four men and four women were enrolled in a 
controlled study called Biosphere 2. They lived for 18 months in a close 
ecosystem, experiencing a forced decrease in calorie intake. The reduced 
energy intake associated to a highly physical activity lowered body weight,  
blood pressure, blood glucose, insulin, cholesterol, triiodothyronine and white 
blood cells (87). 
Similar results were obtained by the Calorie Restriction Society, a group 
composed by volunteers, who had been eating about 1800 kcal/day for an 
average of 6.5 years (30% less calories than age-matched and sex-matched 
volunteers consuming a typical Western diet) (88). Indeed, serum total 
cholesterol, low density lipoprotein cholesterol (LDL), triglycerides, fasting 
glucose, fasting insulin but not  HDL-C, were significantly lower in the CR 
group than in the US diet control group. Moreover, the CR group resulted more 
protected against atherosclerosis and hypertension and diabetes (89). 
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Significant differences in the metabolic and physiologic effect of CR between 
mice and humans have been described. In rodents, CR without protein 
restriction induces a 20–40% reduction in the level of IGF-1 while in humans, 
severe CR without reduction of protein intake does not reduce serum IGF-1 
and IGF-1/IGFBP-3 concentrations. On the other hand, severe reduction of 
protein intake could have a negative impact on human health. These findings 
suggest that it is very important to understand the right rate of daily protein 
intake to protect whole body against stress and disease without side effects 
(90-92). 
 
Calorie restriction: molecular and metabolic aspects 
Several mechanisms have been proposed to explain the biological basis of the 
CR life-prolonging and anti-aging actions. It is not easy to obtain clear and 
supported by evidence answers, but it is certain that CR implicates a 
combination of metabolic, physiological and cellular adaptations to CR itself. 
One of most potent effects of CR is its ability to suppress GH/IGF-1 axis. GH 
directly regulates the production of IGF-I, which is the major mediator of the 
growth effects of GH (79). In humans, IGF-I levels decrease dramatically in 
response to short-term starvation (36–120 hours) despite increased GH 
secretion (93, 94). Notably, the RAS/RAF/MAPK and the PTEN/PI3K/Akt 
pathways, which mediate suppression of apoptosis and contribute to 
proliferation and cell growth, can be down regulated possibly by reducing IGF-I 
(95). These pathways are important in determining the sensitivity of tumors to 
CR, and specific mutations have been shown to confer cancer resistance to 
CR (96). In addition to alteration in IGF-1 signaling, alterations of the insulin 
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and mTOR/Akt/S6K pathways appear to contribute to the effect of CR on 
longevity.  
Another very potent effect of CR is to reduce ROS production and to maintain 
the redox balance. ROS are produced by different cellular sources, such as 
cyclooxygenase (COX), which is involved in inflammation by producing 
prostaglandins, prostacyclin and thromboxane. CR in known to inhibits COX 
activity and ROS related production. COX activity is related to the transcription 
factor NF-κB activity which is responsible for the transcription of many pro-
inflammatory proteins like TNF-α, IL-1, IL-2, and IL-6; chemokines; adhesion 
molecular (AMs), including ICAM-1, VCAM-1, and enzymes such as 
inducible NO synthase (iNOS) and COX-2. However, contradictory results 
were obtained about CR effect on NF-κB activity (97, 98). 
Finally, CR plays an important role in neuroendocrine adaptations, that have 
been hypothesized to be involved in the anti-aging effects of CR. Indeed, CR 
causes: i) reduction of thyroid hormones and cathecolamines that regulate 
thermo genesis and cellular metabolism (ii) decrease of testosterone, estradiol, 
insulin, leptin which are anabolic hormones and iii) increase of glucocorticoids, 
adiponectin and hormones that suppress inflammation (100). 
 
 
 
 
 
 
 
 25 
Short-term-starvation, differential-stress-resistance and cancer. 
Cancer is a complex multistage disease associated with accumulation of 
multiple DNA mutations that cause a deregulation of cell proliferation and 
differentiation, loss of normal tissue organization, and eventually tissue 
invasion and dislocation to distant sites (Figure 9) (101). DNA damage, which 
occurs continuously in both the dividing and non dividing cells of the human 
body, and can increase after exposure to exogenous genotoxic carcinogens, 
can be prevented or repaired by endogenous protective small molecules and 
enzymes.  
 
 
Figure 9. Hallmarks of cancer 
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However, these detoxification and repair systems might fail, particularly in 
environments that promote cell proliferation and inhibit cell apoptosis, but also 
in non-dividing cells in which the opportunity for repair might be limited.  
Accumulation of multiple DNA mutations in critical genes (i.e. oncogenes or 
tumor  suppressor genes) of particular cells, if not properly controlled through 
induction of senescence or apoptosis, can lead to uncontrolled cell proliferation 
and progressive malignant transformation (82). Epidemiological studies have 
shown a significant association between chronic energy imbalance, which 
promotes hypertrophy of adipose tissue, reduced adiponectin production, 
insulin resistance and compensatory hyper-insulinemia, and increased risk of 
cancers (102, 103) . 
Chemotherapy has established itself as one of the pillars of cancer treatment 
and  extend survival in patients diagnosed with a wide range of malignancies. 
However, side effects caused by toxicity to normal cells and tissues limit 
chemotherapy dose intensity, which may compromise efficacy. Thus, reduction 
of undesired toxicity by selective protection of normal cells without 
compromising the killing of malignant cells represents a promising strategy to 
enhance cancer treatment. In this connection, Valter Longo and his co-workers 
demonstrated that non-malignant cells can be induced to turn into a self 
protection mode by conditions of STS (105). In healthy cells, STS was found to 
activate protective metabolic pathways that confer resistance to oxidative 
stress, such as that inflicted by anticancer agents, an effect termed “differential 
stress resistance” (DSR) (Figure 10).  
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Figure 10. Molecular mechanisms at the basis of the Differential-stress-resistance 
 
In striking contrast, cells expressing activated oncogenes are unable to turn on 
the protective response due to uncontrolled activation of growth promoting 
signaling cascades and become even more sensitive to anticancer agents 
(“differential stress sensitization”, DSS). Accordingly, in experiments using 
mouse models of human cancer, fasting specifically augmented the levels of 
oxidative stress and sensitivity to oxidative damage in response to 
chemotherapeutic agents in cancer cells and these effects were accompanied 
by DNA damage and apoptosis. Notably, some of the systemic changes 
induced by fasting, such as hypoglycemia and a marked reduction in the 
circulating levels of IGF-1, are also credited with anticancer activity in vivo. 
The first clinical experience with fasting in patients receiving chemotherapy 
indicates that this dietary intervention is feasible, safe and significantly reduces 
common side effects induced by chemotherapy (Figure 11) (107,108). 
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Furthermore, in those patients whose cancer progression could be assessed, 
fasting does not prevent the chemotherapy-induced reduction of tumor volume 
or tumor markers (107). The discovery that STS may not only alleviate the side 
effects of chemotherapy, but also increase its effects on cancer cells has 
recently attracted further attention to this approach amongst physicians and 
patients, and several pilot trials (NCT01304251, NCT01175837, 
NCT00936364, NCT01175837) are currently exploring fasting in combination 
with chemotherapy in humans.   
 
 
Figure 11. Self reported side effects after chemotherapy with or without fasting 
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Summary of the study 
Tumor chemoresistance is associated with high aerobic glycolysis rates and 
reduced oxidative phosphorylation, a phenomenon called “Warburg effect” 
whose reversal could impair the ability of a wide range of cancer cells to 
survive in the presence or absence of chemotherapy. In previous studies, 
Short-term-starvation (STS) was shown to protect normal cells and organs but 
to sensitize different cancer cell types to chemotherapy but the mechanisms 
responsible for these effects are poorly understood. We tested the cytotoxicity 
of Oxaliplatin (OXP) combined with a 48hour STS on the progression of CT26 
colorectal tumors. STS potentiated the effects of OXP on the suppression of 
colon carcinoma growth and glucose uptake in both in vitro and in vivo models. 
In CT26 cells, STS down-regulated aerobic glycolysis, and glutaminolysis, 
while increasing oxidative phosphorylation. The STS-dependent increase in 
both Complex I and Complex II-dependent O2 consumption was associated 
with increased oxidative stress and reduced ATP synthesis. Chemotherapy 
caused additional toxicity, which was associated with increased 
succinate/Complex II-dependent O2 consumption, elevated oxidative stress 
and apoptosis . 
These findings indicate that the glucose and amino acid deficiency conditions 
imposed by STS promote an anti-Warburg effect characterized by increased 
oxygen consumption but failure to generate ATP, resulting in oxidative damage 
and apoptosis. 
 
Keywords: Fasting; Warburg effect; colon cancer; oxidative phosphorylation; 
glucose uptake  
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Introduction 
Tumor cells are characterized by high glucose uptake and lactate production 
regardless of oxygen concentration, a phenomenon known as the “Warburg 
effect” (11). The metabolic shift toward the Warburg effect confers bioenergetic 
and biosynthetic advantages to proliferating cells by increasing non-oxidative 
ATP production and generating metabolic intermediates from glucose 
important for cell growth (109). Glutamine represents an additional metabolite 
catabolized by tumor cells and utilized for biosynthetic processes (110). 
Aerobic glycolysis and glutaminolysis contribute to the chemoresistance of 
cancer cells (111) through: i) increased lactate production and export, ii) 
elevated NADPH limiting DNA oxidant drug effectiveness, and iii) decreased 
oxidative phosphorylation (OXPHOS) rate leading to reduced reactive oxygen 
species (ROS)-mediated DNA damage (112-114) (115). Therefore, strategies 
inhibiting glycolysis and glutaminolysis and promoting OXPHOS in order to 
delay tumor growth and overcome drug resistance are being investigated  
(116-118). The return of cancer cells to the normal respiratory mode 
maintained by normal cells could also promote cancer cell death if the 
respiration was accompanied by electron leakage and superoxide generation 
(119, 120), leading to cellular damage and apoptosis   (121, 122). 
In mice, two day cycles of water only fasting (short term starvation, STS) cause 
a generalized glucose and amino acid reduction/deficiency, which protects 
normal but not tumor cells against chemotherapy-mediated cytotoxicity (105), 
and induces potent chemosensitizing effects in many tumors (123, 124). 
Preliminary clinical data indicates that in cancer patients fasting is not 
associated with major side effects and may reduce several of the side effects 
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associated to chemotherapy (107) including a decreased toxicity to 
lymphocytes (125). These pre-clinical and preliminary clinical results served as 
the foundation for randomized trials to test the safety and efficacy of fasting 
cycles on the effect of chemotherapy on both normal and cancer cells 
(NCT01304251, NCT01175837, NCT00936364, NCT01175837).  
However, the molecular mechanisms responsible for the chemosensitizing 
effects of fasting and STS on cancer cells remain poorly understood (126) 
(123). 
Here, using both in vitro and in vivo colon carcinoma models, we show that 
STS exerts an anti-Warburg effect driving tumor cells from a glycolytic mode 
into an uncoupled OXPHOS which promotes increased ROS generation and 
apoptosis. These effects are enhanced by chemotherapy treatment. 
 
Results 
Effects of fasting cycles and chemotherapy on colon carcinoma growth 
and glucose consumption in vivo 
We investigated the effect of STS +/- chemotherapy on glucose metabolism in 
CT26 colon carcinoma cells in mice by micro-PET analyses. As previously 
described (105, 123), 48-hour of STS induced a significant body weight loss 
and serum glucose reduction. Analysis of tracer uptake by the tumor showed a 
differential response to the treatments (Figure 12A-C). After the first cycle, STS 
was as effective as OXP in reducing the average tumor glucose consumption 
(Figure 1C). However, the lowest values were achieved by STS+OXP (Figure 
12A-C). Monitoring of tumor progression during multiple cycles revealed that 
average tumor metabolism was inhibited similarly by the first and second STS 
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treatments (Figure 12C). Chemotherapy induced only a transient reduction of 
the lesion metabolic rate after its first application. By contrast, average glucose 
consumption remained significantly lower in STS+OXP-treated mice (Figure 
12C). 
The metabolic response to treatment was paralleled by an evident effect of 
STS on cancer growth, mostly during the fasting and not the post-fasting 
period (Figure 12D). The transient effect of STS on tumor growth was 
repeatable. OXP instead showed a deceleration in cancer growth which was 
enhanced by STS (STS+OXP) (Figure 12D). The additive effect of STS+OXP 
was also evident when total cancer glucose consumption rate was measured 
(tumor glucose metabolism/gr/min x total tumor volume). After both cycles, this 
glucose consumption rate was much lower in either STS- or OXP-treated mice 
but was lowest in STS+OXP-treated mice compared to that in untreated mice 
(STS+OXP vs STS 1° cycle P=0.05; STS+OXP vs OXP 1° cycle P=0.03; 
STS+OXP vs OXP 2° cycle P=0.01) (Figure 12E). In summary, these results 
indicate that STS enhances the toxicity of chemotherapy to colon cancer cells, 
resulting in decreased glucose consumption rates. 
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Figure 12. In vivo effect of fasting cycles in combination with chemotherapy on tumor 
glucose consume and cancer growth. 
CT26 cells were subcutaneously inoculated in the fat pad of BALB/c mice (200.000 
cells/mouse). Five days after tumor cell inoculum, the mice were starved or maintained on the 
ad lib standard diet for 48 hours and treated with Oxaliplatin (OXP) (10 mg/Kg). After 1 week, 
the treatment was repeated. All mice were imaged after the first and the second cycle of 
therapy by a dedicated micro-PET system. 
Panel A shows the Patlak-map of a representative mouse for each group after the first cycle of 
treatment. 
Panel B shows the Patlak-map of a representative mouse for each group after the second 
cycle of treatment. Red arrows indicate the tumor mass. 
Panel C shows the cancer glucose consumption expressed as nMol x min-1 gr. 
Panel D shows the tumor volume expressed as mean value ± SD. Groups of experiments 
include: control (black), STS (green), OXP (light blue), and STS+OXP (red). 
Panel E shows the total cancer glucose consumption expressed as nMol x min-1. 
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In vitro effects of STS and chemotherapy on viability and metabolism of 
colon carcinoma cells 
We investigated the in vitro effects of STS on a panel of colon carcinoma cell 
lines grown under normal or conditions mimicking starvation (123) for 48 
hours. One day after STS, the cells were treated with OXP. STS and OXP 
showed additive cytotoxic effects in all the cell lines (Figure 13A). FDG uptake 
paralleled viability response since it was reduced by a similar degree by each 
single stressor, although the greatest impairment occurred in response to 
STS+OXP (Figure 13B). These results confirm the in vivo results and support 
the use of the in vitro paradigm to model the effects of STS in mice. 
 
 
Figure 13. Effects of STS in combination with chemotherapy on viability and glucose 
uptake by colon carcinoma cells. 
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Tumor cells were cultured in with either low glucose (0.5 g/l) and 1% serum (in vitro STS) or 
the standard glucose levels (1.0 g/l) and 10% serum (control) for 48 hours. Then, cells were 
incubated with 40 M oxaliplatin (OXP) for 24 hours. 
Panel A shows cell viability of different colon carcinoma cell lines (CT26, HCT 116 and HT-29) 
as determined by Trypan Blue Assay. 
Panel B shows 18F-Fluorodeoxyglucose (FDG) uptake by different colon carcinoma cells 
(CT26, HCT 116 and HT-29). Tumor cells were incubated with FDG at 37 KBq/ml for 60 
minutes. FDG retention was measured as the ratio between bound and total radioactivity. 
Data are expressed as percentage of viable cells  ± SD. P value was calculated using 
unpaired t-test with Welch's correction. *: P<0.05; **: P<0.01; ***: P<0.001. 
 
 
Starvation and chemotherapy differentially regulate proliferation and 
metabolic enzymes in colon carcinoma cells 
Because CT26 cells displayed the greatest sensitivity to STS in terms of 
viability and metabolic response (Fig. 14A-B), we selected these cells to 
measure key mediators of proliferation and glucose metabolism in the PI3K-
AKT pathway (PI3K, Phosphatase and Tensin Homolog (PTEN), 3-
Phosphoinositide Dependent Kinase 1 (PDK1) and AKT). The effect of STS on 
metabolism was also evaluated by measuring GLUT1 and GLUT2 (both 
involved in glucose uptake)and the glycolytic enzyme HKII, PFK, Pyruvate 
Kinase (PK), and Lactate Dehydrogenase (LDH) expression and enzymatic 
activity. STS and in particular STS+OXP down-regulated the expression of 
PI3K/p110 (STS vs CTR: 81%; STS+OXP vs CTR: 48%), phospho-PDK1 
(STS vs CTR: 57%; STS+OXP vs CTR: 84%) and phospho-AKT (STS vs CTR: 
75%; STS+OXP vs CTR: 58%) and up-regulated PTEN expression (STS vs 
 36 
CTR: 122%; STS+OXP vs CTR: 121%) (Fig. 3A). Notably, the latter effects 
matched well the effects of the treatments on CT26 proliferation (Figure 15). 
The effects of STS on proteins involved in glucose transport and metabolism 
was even more evident: STS induced a profound reduction in GLUT1 (STS vs 
CTR: 15%),GLUT2 (STS vs CTR: 40%), HKII (STS vs CTR: 74%; STS+OXP 
vs CTR: 48%), PFK1 (STS vs CTR: 74%; STS+OXP vs CTR: 48%), PK (STS 
vsCTR:64%;STS+OXP vs CTR: 66%) protein expression, particularly in 
combination with chemotherapy (Fig. 14A).  
HK II catalytic function was reduced by all treatments (Figure 14B) but its 
intracellular localization was also affected. Immunofluorescence analysis 
showed a re-localization of HK II from the mitochondrial membrane into the 
cytosol, particularly after STS+OXP treatment (Figure 14C). Glucose 
metabolism impairment was further aggravated by the concomitant reduction 
of PFK (Figure 14D), PK  (Figure 14E) and LDH (Figure 14F) activity caused 
by all treatments. STS-associated impairment of enzymes involved in glucose 
metabolism was confirmed by the analysis of extracellular lactate 
concentration, which was markedly reduced by STS alone or in combination 
with OXP (Figure 14G). 
The STS-mediated reduction of glucose catabolism and expression of 
transport enzymes is consistent with the reduced levels of glucose caused by 
STS but also with the possibility that STS conditions promote a Warburg 
reversing effect . 
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Expression of glycolytic and glutaminolytic enzymes in response to STS 
and chemotherapy 
The transcriptome and proteome of STS- and OXP-treated CT26 cells were 
analyzed by oligonucleotide micorarrays and Label Free Quantitation (LFQ) on 
High Resolution/Mass Accuracy Liquid Chromatography Tandem Mass 
Spectrometry (HR/MA LC MS/MS), respectively. Figure 14H shows a heat map 
of proteins involved in glycolysis and glutaminolysis. The down-regulation of 
glycolytic enzymes was observed in STS-treated CT26 cells (Figure 14H), with 
or without OXP treatment. This down-regulation is most likely due to an effect 
of STS at the transcriptional level since the expression profiles of STS-treated 
cells show a clear down-regulation of the genes encoding these enzymes 
(Figure 14I). At the gene expression level, OXP-treated cells also show 
reduced expression of glycolysis genes but this effect is more evident in 
STS+OXP-treated cells (Figure 14I). STS also reduced both glutaminase (Gls) 
mRNA and protein levels. In contrast, the expression of the glutamine 
transporter Slc1a5 was reduced only at the protein level (Figure 14H-I). The 
combination of STS+OXP reduced protein and mRNA levels of both 
glutaminase and the Slc5a1 (Figure 14H-I). These results confirm that the 
reduced glucose levels in combination with other changes imposed by STS, 
have a major effect in down-regulating glycolytic genes and proteins. 
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Figure 14 Effect of STS in combination with chemotherapy on growth and glucose 
metabolism pathways in colon carcinoma cells. 
CT26 colon carcinoma cells, undergoing STS or incubated under standard conditions and 
treated with or without 40 µM oxaliplatin (OXP) for 24 hours, were lysed and either western 
blots or enzymatic activities were measured. For protein expression analysis cells were lysed 
and injected in a nanoscale high-performance liquid chromatography system connected to a 
hybrid linear trap quadrupole (LTQ) Orbitrap mass spectrometer. Proteins were identified and 
quantified using  MaxQuant pipeline. For gene expression analysis RNA was extracted from 
CT26 cells and analyzed by microarray hybridization. 
PanelA shows the expression of PI3K, PTEN, Phospho-PDK1, Phospho-AKT, GLUT1, 
GLUT2, HKII, PFK1, PK and -actin. 
Panel B shows the overall activity of HK by CT26 cells. 
Panel C shows the confocal microscopy for HK II. After treatment the cells were labeled by 
MitoTracker Far Red and stained for HK II expression by immunofluorescence. Merged 
images indicate that STS+OXP causes a significant and selective dislocation of HK II isoform 
from mitochondrial membrane to the cytosol. 
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Panel D-E-F show  the activity of Phosphofructokinase (PFK), Pyruvate kinase (PK), Lactate 
Dehydrogenase (LDH) by CT26 cells, respectively. 
Panel G shows the lactate release measured by spectrometry in the supernatants of CT26 
cells. Data are expressed as mean values ± SD. P value was calculated using unpaired t test 
with Welch's correction. *: P<0.05; **: P<0.01; ***: P<0.001. 
Representative expression heat maps of proteins (Panel H) and genes (Panel I) involved in 
glycolysis and glutaminolysis are shown. Data are expressed as ratios over mean values for 
the four conditions (STS, OXP, STS+OXP; red = expression above mean, black= expression 
at mean; blue = expression below mean) 
 
 
Figure 15. Effects of starvation in combination with chemotherapy on proliferation of 
CT26 colon carcinoma cell lines. 
CSFE labeled CT26 colon carcinoma cells were cultured in normal (1.0 g/L glucose + 10% 
FBS) or starved (0.5 g/L glucose + 1% FBS) conditions 48 hours. Cells were incubated with 40 
M oxaliplatin (OXP) for 24 hours. CSFE stained cells were analyzed by cytofluorimetry. MFI 
= mean fluorescence intensity. 
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Starvation and chemotherapy promote uncoupling of the mitochondrial 
respiratory chain and oxidative stress 
Proteomic and genomic analyses did not show a clear effect of STS in up- 
regulating OXPHOS although different sets of respiratory enzymes were 
elevated after STS or OXP or STS+OXP (Figure 16A-B). Clear changes were 
instead observed when measuring enzymatic activities of respiratory 
complexes, oxygen consumption and ATP: STS up-regulated Complex I and 
IV (Figure 17A and C) without affecting Complex II activity (Figure 17B). 
Consistent with this, a significant increase in O2 consumption rate (OCR), 
indicative of an increased oxidative metabolism, was observed (Figure 17D-E). 
This corresponded to a significant reduction of ATP synthesis (Figure 17F and 
G). Accordingly, the ATP/AMP ratio, a good indicator of cellular energy charge, 
was dramatically reduced by the two STS settings (Figure  16C). 
 
 
Figure 16. Expression of oxidative phosphorylation enzymes and energy charge in 
response to starvation and chemotherapy in colon carcinoma cell lines 
CT26 colon carcinoma cells were starved or not and treated with or without 40 M oxaliplatin 
(OXP)  for 24 hours. For protein expression analysis (Panel A) cells  were lysed and injected in 
nanoscale high-performance liquid chromatography system connected to a hybrid linear trap 
quadrupole (LTQ) Orbitrap mass spectrometer. Proteins were identified and quantified using 
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MaxQuant pipeline. For gene expression analysis (Panel B) RNA was extracted from CT26 
cells and  analyzed by microarray hybridization. Representative expression heatmaps of 
proteins (Panel A) and genes (Panel B) involved in oxidative phosphorylation are shown.Data 
are expressed as ratios over mean values for the four conditions (STS, OXP, STS+OXP; red = 
expression above mean, black = expression at mean; blue = expression below mean) 
Panel C shows the ATP/AMP ratio evaluated by spectrometry in CT26, treated with or without 
STS, OXP or STS + OXP. Data are expressed as the mean value ± SD of  ATP/AMP ratio. 
 
In order to confirm the stimulatory effect of STS on Complex I-activity, we pre-
incubated CT26 cells with Rotenone, a Complex I inhibitor. In the presence of 
Rotenone, none of the treatments caused a significant OCR increase (Figure 
17H) or ATP synthesis reduction (Figure 17I). 
 
 
Figure 17. Effect of STS in combination with chemotherapy on oxidative 
phosphorylation activity of CT26 colon carcinoma cells. 
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Panels A, B and C report the activity of the redox Complexes I, II and IV in CT26 cell lines 
treated with STS +/- OXP. Data are expressed as mean values ± SD. P value was calculated 
using unpaired t-test with Welch's correction. *: P<0.05. 
Panels D-E show the oxygen consumption rate (OCR) of CT26 in the presence of  pyruvate  
(10mM)/malate (5mM) and succinate (20mM), respectively. OCR was measured by an oxygen 
micro-respiration electrode and expressed as µM O2/min/106 cells.  Each  is representative of 
at least three experiments. 
Panels F-G describe the activity of F0-F1 ATP synthase of CT26 cell lines, measured by 
luminometric analysis, after the addition of 10 mM pyruvate + 5 mM malate or 20 mM 
succinate. 
Panels H-I show the OCR and ATP synthesis in CT26 cells in the presence of pyruvate  
(10mM)/malate (5mM) and pre-incubated with Rotenone. 
Each  is representative of at least six experiments. P value was calculated using unpaired t-
test with Welch's correction. *: P<0.05. 
 
Increased activity of the mitochondrial respiratory chain with a decreased ATP 
production suggests a possible increase in superoxide generation caused by 
electron leakage, possibly at complex I and III (127). Indeed, STS and OXP 
markedly increased ROS generation in CT26 cells and STS+OXP further 
exacerbated ROS production (Figure 18A). These profound metabolic 
alterations, characterized by reduced ATP biosynthesis and increased ROS 
production, are likely responsible for the additive effect of STS+OXP in 
triggering apoptosis in CT26 cells (Figure 18B-C). 
This response was confirmed by proteomic analyses (Figure 18D) 
documenting an apoptotic signature obtained by hierarchical clustering of a 
110 apoptotic proteins (GO:0006915) (128). STS, OXP and especially 
STS+OXP induced the expression of many pro-apoptotic proteins (Figure 
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18D). In summary, these results strongly support the effect of STS on reducing 
glycolysis and lactate production and increasing respiration at Complexes I-IV 
resulting in superoxide production/oxidative stress but in reduced ATP 
generation. 
 
 
Figure 18. Effect of STS in combination with chemotherapy on reactive oxygen species 
production and apoptosis of colon carcinoma cells. 
Panel A shows the oxidation state of the dye Dichlorodihydrofluoresceindiacetate (DCFDA) as 
a method to assess the level of reactive oxygen species (ROS) in CT26 colon carcinoma cells, 
undergoing STS (48 hours) or under standard conditions, and treated with or without 100µM 
oxaliplatin (OXP) for 24 hours. Results are expressed as mean of the percentage of DCFDA 
positive cells from three different experiments. 
Panel B shows a representative dot plot of CT26 cells, undergoing STS or under standard 
conditions, treated with or without OXP (100µM) and stained with FITC Annexin V and 
propidium iodide (PI). Red squares indicate the percentage of Annexin+/PI-and 
Annexin+/PI+apoptotic cells (early and late apoptosis). 
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Panel C shows the percentage of Annexin+/PI-and Annexin+/PI+apoptotic CT26 cells expressed 
as mean value ± SD from three different experiments performed. P value was calculated using 
Unpaired t test with Welch's correction. *: P<0.05; **: P<0.01. 
Panel D shows a representative heat map of proteins annotated by Gene Ontology as involved 
in apoptosis. Data are expressed as ratios over mean values for the four conditions (STS, 
OXP, STS+OXP; red = expression above mean, yellow = expression at mean; blue = 
expression below mean). 
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Discussion 
Our results indicate that STS, defined as a water only diet lasting 2 days in 
mice or severe serum plus glucose glucose restriction in vitro, causes a 
profound metabolic shift and promotes an anti-Warburg effect in colon cancer 
cells. We show that STS in vitro down-regulates glycolysis and glutaminolysis 
and increases OXPHOS and OCR, reduces ATP synthesis and increased 
ROS production. This latter effect is presumably associated with the induction 
of apoptosis. Chemotherapy increased this toxicity further by inducing both 
Complex  I and Complex II-dependent respiration, leading to elevated toxic 
oxygen species generation but reduced ATP generation and death. 
Cancer cells alter their metabolism in order to satisfy their bioenergetic and 
biosynthetic requirements, generating a peculiar metabolic pattern 
characterized by high anaerobic glycolysis, fatty acid synthesis and glutamine 
metabolism (11). Aerobic glycolysis produces higher ATP and NADH levels 
(129, 130) which may contribute to chemoresistance through increased drug 
efflux from the cell, enhanced DNA repair, dysregulation of growth factor 
signaling and high expression of survival pathways or anti-apoptotic genes 
(131). For these reasons, the combination of chemotherapy and agents able to 
affect the ability of cancer cells to adopt alternate metabolic strategies and 
survive represents a promising strategy to overcome drug resistance and 
improve chemotherapeutic index (132). Therapies targeting cancer metabolism 
such as calorie restriction and ketogenic diet (96, 133) can modify the 
metabolic state of the whole organism but also that of the tumor cells. Part of 
the effects of STS can be achieved by agents that target metabolic enzymes 
including glucose transporters, hexokinase, pyruvate kinase M2, lactate 
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dehydrogenase, lactate transporter, and glutaminase (111). However, STS 
provides 2 advantages: 1) in both mice and humans it causes virtually no 
severe side effects, 2) it affects the function of hundreds of proteins and 
enzymes thus increasing the chance of affecting a pathway required for tumor 
cell survival, particularly under the already hostile environment generated by 
chemotherapy. 
Multiple cycles of STS have been shown to protect normal cells against 
chemotoxicity and to increase the effectiveness of chemotherapeutic drugs 
against the survival and progression of various tumor types (105, 106). 
However, whether STS sensitizes tumor cells to chemotherapy by affecting 
their metabolism is presently unknown. In agreement with previous reports 
(123, 124, 126), our present results demonstrate that STS, especially in 
combination with chemotherapy,  delays the in vivo and in vitro  growth of 
colon carcinoma cells. We show that STS significantly reduces cancer glucose 
consumption leading to a transient arrest in cancer progression followed by a 
rebound phase after re-feeding. By contrast, STS+OXP causes a more severe 
metabolic impairment and a long-lasting decrease in cancer growth. Both 
observations confirm the relationship between glucose consumption and 
proliferation rate in cancer. 
The profound metabolic alterations observed in tumor cells are often related to 
induction of PI3K-AKT signaling, which plays a pivotal role in glucose 
metabolism and cancer growth control (11). Phosphorylated AKT has been 
shown to: i) up-regulate the expression of glucose transporters , ii) enhance 
glucose capture by HK and iii) to stimulate PFK (109). Our study indicates that 
STS down-regulates PI3K, AKT, and PDK1 phosphorylation in CT26 colon 
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carcinoma cells. In contrast, the expression of PTEN, which negatively 
regulates PI3K-AKT signaling, is significantly induced by STS. 
Colon carcinoma cells cultured under starvation conditions exhibit a significant 
reduction of glucose avidity and consumption.  GLUT1, a member of the GLUT 
(SLC2A) family of membrane transporters that mediates glucose import, is 
frequently overexpressed in many cancers. Its inhibition can overcome tumor 
chemoresistance and improve the therapeutic effect of chemodrugs (59, 134, 
135). In CT26 cells, glucose intake is known to be mainly dependent on 
GLUT1 and GLUT2 whose expression levels are dramatically down-regulated 
by STS. Glucose consumption and the start of the glycolytic process in cancer 
depends on HK II whose catalytic function is largely empowered by its p-AKT-
dependent binding to the outer mitochondrial membrane (136). We show that 
STS hampers this association which may limit the preferential access of HK II 
to ATP for glucose-6-phosphate production. STS also limits PFK,PK and LDH 
activity, which will directly inhibit the rate-limiting steps of glycolytic flux. In 
addition, STS dramatically reduces the lactate released by CT26 cells, likely 
due to the concomitant down-regulation of MCT1/Scl16a1 and CD147 (data 
not shown).The acidification of the tumor microenvironment due to high levels 
of exported lactate can hamper antitumor immune responses and favor tumor 
metastasis (137, 14). Also, intracellular lactate may be converted to pyruvate 
by LDH and used as a nutrient source for oxidative metabolism and/or 
gluconeogenesis.  Marked increase of LDHA, MCT1/4 and CD147 levels 
correlate with cancer progression and drug resistance (138-140) and the 
targeting of LDHA and MCT has been proposed as a cancer therapy (141-
145). Thus, the effect of STS on glycolysis and lactate production alone, could 
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cause a major effect on cancer progression, even independently of its effects 
on mitochondria. 
The inhibition of glucose utilization is accompanied by a down-regulatory effect 
of STS on the glutamine transporters Slc1a5 and glutaminase, which catalyze 
glutamine catabolism and provide cancer cells with bio-synthetic precursors for 
aminoacids and DNA synthesis (146, 147). As a metabolic counterpart of 
glycolysis inhibition, STS induces ROS levels and apoptosis, probably as the 
result of a futile enhancement of mitochondrial complex activity uncoupled from 
ATP synthesis. Mitochondrial OXPHOS is the major cellular source of ROS, 
mainly through the activity of complex I and III. The most likely explanation for 
the increase in Complex I and IV activities, accompanied by increased OCR 
but reduced ATP generation and elevated ROS production after STS, OXP or 
their combination is that the cancer cells are not able to synthesize ATP at the 
rate dictated by oxygen consumption therefore increasing the electron leakage 
at Complexes I and III to form superoxide (11, 44, 127) (Figure 19). Higher 
superoxide and lower ATP could then promotes cell death in part through 
ROS-induced apoptosis (148, 149, 119). On the other hand, OXP, as a 
chemotherapeutic agent, provokes DNA damage dependent apoptosis. Hence, 
the apoptotic activities induced by STS and chemotherapy complement each 
other. In conclusion, the present study indicates that the combination of STS 
cycles and chemotherapy causes a major enhancement of chemotherapeutic 
index, in part by promoting an anti-Warburg effect characterized by reduced 
glycolysis, reduced lactate generation, and increased oxidative 
phosphorylation with lower ATP synthesis but higher ROS generation and 
apoptosis. 
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Figure 19. A Model of Short term starvation effects on the metabolism of the tumor cell 
Starvation in terms of reduced availability of glucose and aminoacids  in the extracellular 
space determines a reduced expression of the glucose transporters Glut1 and Glut2 and leads 
to a general reduction in the glycolytic rate through the down-regulation of gene and protein 
expression as well as activity of almost all enzymes of the glycolytic chain. As a consequence, 
the production and secretion of lactate is reduced, with potential effects on the tumor 
microenvironment. This  anti-Warburg effect is also accompanied  by increased  activities of 
complexes I, III and IV of the respiratory chain. However, uncoupling of respiration leads to the 
production of increased amounts of free oxygen radicals that determine an enhanced oxidative 
damage to the nuclear DNA. This latter event  is responsible for the induction of  apoptotic cell 
death. Uncoupling also causes a reduced activity of complex V of the respiratory chain 
resulting in ATP deficiency which makes tumor cell more  vulnerable to the chemotherapeutic 
insult.  
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Material and methods 
Cell lines and culture conditions 
Tumor cell lines were cultured in DMEM medium (Euroclone, Milan, Italy) 
supplemented with 1% L-glutamine, penicillin/streptomycin, nonessential 
amino acids and 10% fetal bovine serum (FBS) (all from Sigma Aldrich, Milan, 
Italy) (complete medium). All treatments were performed at 37oC under 5% 
CO2. Glucose restriction was done by incubating cells in glucose free DMEM 
(Invitrogen, Monza, Italy) supplemented with either low glucose (0.5 g/L) or 
normal glucose (1.0 g/L) for 48 hours Serum restriction was done by incubating 
cells in DMEM/F12 with either 10% or 1% FBS for 48 hours. Oxaliplatin (OXP, 
Hospira, Naples, Italy) treatment was performed 24 hours after STS in a 
concentration range between 10-100 µM.  Optimum drug doses were 
determined for each individual cell line. 
 
Cell viability, proliferation and apoptosis assays 
Colon cancer cell lines were plated in 12-well plates (Falcon, Becton 
Dickinson, Le Pont de Claix, France) (CT26 and HCT 116 1×105, HT-29 2×105, 
cells per well) in complete medium. After 24 hours media were switched to 
starvation (0.5 g/L glucose + 1% FBS) or control (1 g/L glucose + 10% FBS) 
and 48 hours later cells were harvested and the number was assessed by 
Trypan blue (Sigma Aldrich) exclusion. To asses proliferation, cancer cells 
were labeled with 20µM CarboxyfluoresceinSuccinimidyl ester (CFSE) 
(Invitrogen, Milano, Italy) for 15 minutes at 37°C and treated as above 
described. Then, cells were acquired with a Gallios cytometer.  
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Immunofluorescence analysis 
CT26 cells were incubated with MitoTracker probe (Life Technologies Italia, 
Monza, Italy) and treated as previously described (150). Coverslips were 
incubated overnight with rabbit anti-HKI (C35C4) or anti-HKII (C64G5) primary 
antibodies (Cell Signaling Technologies, Leiden, The Netherlands). Specific 
staining was visualized with a goat anti-Rabbit Alexa Fluor 488 secondary 
antibody (Molecular Probe® Life Technology), washed and mounted using 
Prolong Gold anti-fading reagent (Life Technologies). Results were analyzed 
using an Olympus (Olympus Optical) laser-scanning microscope FV500 
equipped with an Olympus IX81 inverted microscope and Argon ion 488 nm, 
He-Ne 543 nm, and He-Ne 633 nm lasers. Digital images were acquired 
through a PLAPO 60× objective, with the Fluoview 4.3b software program, 
sequentially as single trans-cellular optical sections. Spatial co-localization was 
analyzed by Image J 1.34f software (NIH). 
Western blotting  
The antibodies used were as follows: anti-PTEN (Millipore), anti-Phospho-AKT 
(Ser473), anti-Phospho-PDK1, anti-PI3K, anti-HKII, anti-PFK1, anti-PKM2, 
anti-β-actin (all from Cell Signaling), and anti-GLUT1, GLUT2, GLUT3, GLUT4 
(all from Cell Abcam, United Kingdom). 
Spectrophotometric enzymes assay  
Glycolytic enzymes were assayed at room temperature on 25 µg of CT26 cells  
protein, in a double beam spectrophotometer (UNICAM UV2, Analytical S.n.c., 
Italy) as previously described (151). 
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The activity assay of the redox complexes I, II, III, IV  was evaluated as 
described in (152, 153). 
ATP and AMP were measured according to the enzyme coupling method 
described elsewhere (154). 
 
Oxygraphic measurements 
O2 consumption was measured at 25 °C in a closed chamber, using a 
thermostatically controlled oxygraph apparatus equipped with amperometric 
electrode (Microrespiration, Unisense A/S, Århus, Denmark) as described 
(155). In some experiments, CT26 cells were pre-incubated with 50 M 
Rotenone (Sigma) 5 minutes before performing O2 measure. 
 
Bioluminescent luciferase ATP assay 
Fifty micorgrams of CT26 cell proteins were incubated in an appropriate buffer 
plus 5 mM pyruvate and 2.5 mM malate as described in (156) and ATP 
synthesis was then induced adding 0.1 mM ADP. ATP concentration was 
measured in a luminometer (Lumi-Scint, Bioscan) by the luciferin/luciferase 
chemiluminescent method (157). In some experiments, CT26 cells were pre-
incubated with 50 µM Rotenone (Sigma) 5 minutes before performing ATP 
measure. In all experiments the ATP synthesis rate was linear for the first 2 
minutes.  
 
Proteomic analysis 
The MS instrument was operated in data-dependent mode to automatically 
switch between full-scan MS and MS/MS acquisition. Survey full-scan MS 
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spectra were acquired in the Orbitrap analyzer with resolution R = 60,000. The 
20 most intense peptide ions with charge states ≥ 2 were sequentially isolated 
and fragmented by collision-induced dissociation (CID) in the LTQ mass 
spectrometer. Raw mass spectrometric data were analyzed using the 
MaxQuant pipeline (158). Moreover quantification and data normalization were 
achieved by an intensity-based label-free approach using MaxQuant. Thanks 
to the implementation of maximal peptide ratio extraction and delayed 
normalization algorithms, the MaxLFQ program included in MaxQuant, provide 
accurate XIC-based quantification (159). The statistical and the pathways 
analysis have been made with the freely available Perseus 
(www.perseusframework.org/Perseus_1.4.1.3.zip) and Cytoscape software 
respectively  (160).  
 
Microarray 
RNA was extracted from cell lines using RNeasy (Qiagen, Hilden, Germany). 
RNA quality was assessed in the BioAnalyzer (Agilent, St. Clara, CA). cDNA, 
ds-cDNA and cRNA synthesis was performed using the 3' IVT Express Kit 
(Affymetrix, Santa Clara, CA, USA) according to the manufacturer's 
instructions. cRNAs were purified using the RNeasy Mini Kit (Qiagen), 
controlled by agarose gel electrophoresis and subjected to fragmentation for 
35 min. at 94°C in fragmentation buffer (40mM Tris-acetate pH 8.1, 100mM 
CH3COOH, 30mM Mg(CH3COO)2x4H2O). Hybridization, washing and 
staining were performed using the GeneAtlas® Hybridization, Wash, and Stain 
Kit for 3' IVT Arrays (Affymetrix, St. Clara, CA). 
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Mouse models 
To establish a subcutaneous cancer mouse model, 6 week-old female BALB/c 
mice were injected subcutaneously in the lower back with  100L CT26 colon 
cancer cells resuspended in PBS at a density of 2x106 cells/mL (2x105 
cells/mouse). Five days after tumor cell inoculum, when tumors were palpable, 
the animals were subdivided into four groups: “Controls” (N=7) with tumor and 
no treatment which were kept under standard conditions for the whole duration 
of the study; “STS” animals (N=7) that were submitted to 48-hour STS, “OXP” 
mice (N=7) treated with OXP for 24 hours, “STS+OXP” mice (N=7) submitted 
to both treatments. At the end of all treatments mice were submitted to micro-
PET imaging. STS consisted in a complete food deprivation with free access to 
water. “STS” mice were individually housed in a clean new cage to reduce 
cannibalism and were monitored daily for weight loss and general behavior. 
“OXP” mice were inoculated intraperitoneally (ip) with OXP at 10 mg/Kg and 
housed in the presence of food. Tumor size was measured by caliper and 
tumor volume was calculated using the following equation: tumor volume 
(mm3) = (length × width × height) x pi/6, expressing length, width and height in 
mm.  
 
Fluorodeoxyglucose Uptake Evaluation  
Daily quality controls always documented adequate standards and, in 
particular, a radiochemical purity ≥ 98%. Labeling was performed by incubating 
106 cells with FDG according to a procedure validated in our laboratory (150, 
161). Immediately before the experiment, glucose free medium was added with 
two mL PBS containing  FDG at a concentration of 37 KBq/mL. Tracer 
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exposure was maintained for 60 minutes at 37°C. Thereafter, the uptake 
process was stopped by adding 4 ml of PBS before centrifugation at 450 g for 
10 minutes. Supernatant was removed and cell pellet re-suspended in 1ml of 
saline buffer. Free and bound activities were thus simultaneously counted 
using a Packard Cobra II gamma counter (Packard, Meriden, CT) with a 10% 
energy window centered at 511KeV. FDG retention was measured as the ratio 
between bound and total radioactivity. In all cases, the labeling procedure did 
not affect cell viability as documented by Trypan blue staining. 
 
In vivo micro-PET 
Mice were weighted and anesthesia was induced by ip administration of 
ketamine (100 mg/Kg) (IMALGERE 1000, Milan, Italy) /xylazine (10 mg/kg) 
(BIO98 Srl, Milan, Italy). Serum glucose level was tested and animals were 
positioned on the bed of a dedicated micro-PET system (Albira, Carestream 
Inc, US) whose two-ring configuration permits to cover the whole animal body 
in a single bed position. A dose of 3-4 MBq of FDG was then injected through 
a tail vein, soon after start of a list mode acquisition lasting 50 minutes. 
 
In vivo image processing. 
PET data were reconstructed using a maximal likelihood expectation 
maximization method (MLEM). An experienced observer, unaware of the 
experimental type of analyzed mouse, identified a volume of interest (VOI) in 
the left ventricular chamber. Then, the computer was asked to plot the time-
concentration curve within this VOI throughout the whole acquisition to define 
tracer input function. Whole body FDG clearance (in ml x min-1) was calculated 
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using the conventional stochastic approach as the ratio between injected dose 
and integral of input function from 0 to infinity, fitting the last 20 minutes with a 
mono-exponential function (162). A further VOI was drawn over cancer lesion 
to measure maximal standardized uptake value (SUV), i.e. the most commonly 
accepted index of tissue FDG uptake, expressed as the fraction of injected 
tracer dose normalized for body weight.  
Tumor glucose consumption  was expressed in nM X min-1 X g-1 and was 
estimated in this last VOI according to Gjedde-Patlak (163) graphical analysis 
by using the routine of a dedicated software (PMOD, Zurich, Switzerland). 
Briefly, the software utilizes the input function to transform the original tissue 
activity measurements by fitting the data in each voxel with the slope of the 
regression line defined by the model. In all cases, lumped constant value was 
set at 1. 
 
Statistical analysis 
The in vivo data are presented as mean ± standard deviation (SD). For 
comparison between different groups, the Null hypothesis was tested by a 
single factor analysis of variance (ANOVA) for multiple groups. Statistical 
significance was considered for p values p<0.05.  
For in vitro experiments, the statistical significance of differences between 
experimental and control groups was assessed by Unpaired t test with Welch's 
correction using GraphPad Prism 3.0 software (GraphPad Software, Inc, El 
Camino Real, San Diego, CA). 
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